SLC5A2 and diabetes mellitus: A recent guideline of the European Society of Cardiology and European Association for the Study of Diabetes for diabetes, pre-diabetes and cardiovascular diseases recommends SGLT2 inhibitors be administered to reduce the risk of heart failure hospitalization [30].